Kannalife Sciences Participates in 27th Annual International Cannabinoid Research Society (ICRS) Symposium
Company Presents Science Behind Mechanism of Action of CBD and its Own Patented CBD-derived Molecule KLS-13019
NEW YORK, July 5, 2017 — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, announced today that it presented its findings at the 27th Annual ICRS Symposium on the Cannabinoids held in Montreal, Canada from June 22-27, 2017. The Company presented one of its published bodies of science titled the “Effect of KLS-13019 and Cannabidiol On Neuroprotection from Oxidative Stress in Hippocampal Cultures: Mechanism of Action” and two posters at the Symposium.
The publication and two posters Kannalife presented at the Symposium, titled “Neuroprotective and Anti-Inflammatory Effects of KLS-13109 and Cannabidiol in IN VITRO and IN VIVO Models of Chemotherapy-Induced Neuropathic Pain” and “Discovery of Side-Chain Modified Cannabidiol-Derived Neuroprotective Agents with Improved “Drug Likeness,” highlighted the Company’s recent research of CBD and CBD-derived molecule target drug candidates to treat neurodegenerative diseases.
“When we set out to design a better molecule and keep much of the pharmacological properties of CBD such as neuroprotection and reducing oxidative stress, we hoped to come up with an answer to the limitations of CBD,” said CEO of Kannalife, Dean Petkanas. “We believe we’ve answered that problem with KLS-13019. Accordingly, we were honored and grateful to be given the opportunity by the ICRS to present our Company’s most recent research and progress in the field of cannabinoid-based therapeutics. The ICRS is dedicated to promoting the exchange of scientific information and perspectives about the use of cannabis, cannabinoid therapeutics, in the regulation of receptors, neurotransmitters and homeostasis of the endocannabinoid system. Their involvement in sponsoring an annual event that pushes forth the field of scientific discovery in cannabinoid therapeutics is unparalleled.”
Kannalife currently holds a patent on KLS-13019 and other new chemical entities (NCEs) in this class of cannabidiol-derived molecules. The Company also holds two license agreements with the National Institutes of Health (NIH) to utilize the US Government Patent (#6,630,507) on the therapeutic usage of cannabinoids, which derive from the cannabis plant family (industrial hemp or marijuana). The Company is presently conducting research at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (HE), Chemotherapy Induced Neuropathic Pain (CINP) and Chronic Traumatic Encephalopathy (CTE). Both HE and CTE are oxidative stress diseases that affect cognitive and behavioral function.
About Kannalife Sciences, Inc. – A Phyto-Medical Company™
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com.